Lipocine
LPCN
19 hedge funds and large institutions have $1.35M invested in Lipocine in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.
39,600% more call options, than puts
Call options by funds: $397K | Put options by funds: $1K
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0.29% less ownership
Funds ownership: 9.4% → 9.11% (-0.29%)
9% less capital invested
Capital invested by funds: $1.48M → $1.35M (-$137K)
10% less funds holding
Funds holding: 21 → 19 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$82.7K |
| 2 |
Renaissance Technologies
New York
|
+$8.46K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.25K |
| 4 |
Morgan Stanley
New York
|
+$1.91K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$82 |
Top Sellers
| 1 |
Two Sigma Advisers
New York
|
-$81.2K |
| 2 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$49.8K |
| 3 |
WE
Wealth Effects
Boston,
Massachusetts
|
-$10.9K |
| 4 |
CG
Cutler Group
San Francisco,
California
|
-$2K |
| 5 |
JP Morgan Chase
New York
|
-$460 |
LPCN Hedge Fund Activity: Q4 2023 in Review
19 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2023, worth a combined $1.35M — down 9.2% from $1.48M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LPCN and 1 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Susquehanna International Group, adding an estimated $82.7K. The largest seller was Two Sigma Advisers, cutting an estimated $81.2K.
- 19 institutional investors held Lipocine (LPCN) as of Q4 2023, down from 21 in Q3 2023.
- Funds reported $1.35M of Lipocine stock for Q4 2023, down 9.2% quarter-over-quarter.
- 1 fund opened new Lipocine positions in Q4 2023 and 3 closed out, a net change of -2 holders.
- The largest Lipocine buyer in Q4 2023 was Susquehanna International Group, an estimated $82.7K added.
- The largest Lipocine seller in Q4 2023 was Two Sigma Advisers, an estimated $81.2K sold.
Based on aggregated 13F filings for Q4 2023.